Citation: | FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302 |
[1] |
Mokdad AA,Lopez AD,Shahraz S,et al.Liver cirrhosis mortality in 187 countries between 1980 and 2010:a systematic analysis[J].BMC Med,2014,12(1):145.
|
[2] |
Hernandez-Gea V,Friedman SL.Pathogenesis of liver fibrosis[J].Annu Rev Pathol,2011,6(1):425-456.
|
[3] |
Cheng AL,Kang YK,Chen Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
|
[4] |
Raghu G,Johnson WC,Lockhart D,et al.Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent,pirfenidone:results of a prospective,open-label phase II study[J].Am J Respir Crit Care Med,1999,159(4 Pt 1):1061-1069.
|
[5] |
van Dijk F,Olinga P,Poelstra K,et al.Targeted therapies in liver fibrosis:combining the best parts of platelet-derived growth factor BB and interferon gamma[J].Front Med(Lausanne),2015,2:72.
|
[6] |
Lin TsT,Gao DY,Liu YC,et al.Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis[J].J Control Release,2016,221:62-70.
|
[7] |
Bisht S,Khan MA,Bekhit M,et al.A polymeric nanoparticle formulation of curcumin(NanoCurc)ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation[J].Lab Invest,2011,91(9):1383-1395.
|
[8] |
Kumar V,Mondal G,Dutta R,et al.Co-delivery of small molecule hedgehog inhibitor and miRNA for treating liver fibrosis[J].Biomaterials,2016,76:144-156.
|
[9] |
Kumar V,Mundra V,Mahato R I.Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.[J].Pharm Res,2014,31(5):1158-1169.
|
[10] |
Kong WH,Park K,Lee MY,et al.Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis[J].Biomaterials,2013,34(2):542-551.
|
[11] |
Jiménez Calvente C,Sehgal A,Popov Y,et al.Specific hepatic delivery of procollagen 1(I)small interfering RNA in lipid-like nanoparticles resolves liver fibrosis[J].Hepatology,2015,62(4):1285-1297.
|
[12] |
Li FQ,Su H,Wang J,et al.Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting[J].Int J Pharm,2008,349(1/2):274-82.
|
[13] |
Lam PL,Kok SHL,Gambari R,et al.Evaluation of berberine/bovine serum albumin nanoparticles for liver fibrosis therapy[J].Green Chem,2015,17:1640-1646.
|
[14] |
He Q,Zhang J,Chen F,et al.An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles[J].Biomaterials,2010,31(30):7785-7796.
|
[15] |
Nishimori H,Kondoh M,Isoda K,et al.Silica nanoparticles as hepatotoxicants[J].Eur J Pharm Biopharm,2009,72(3):496-501.
|
[16] |
Chen Q, Xue Y, Sun J. Kupffer cell-mediated hepatic injury induced by silica nanoparticles in vitro and in vivo[J].Int J Nanomed,2013,8:1129-1140.
|
[17] |
Liu T,Li L,Fu C,et al.Pathological mechanisms of liver injury caused by continuous intraperitoneal injection of silica nanoparticles[J].Biomaterials,2012,33(7):2399-2407.
|
[18] |
Isoda K,Hasezaki T,Kondoh M,et al.Effect of surface charge on nano-sized silica particles-induced liver injury[J].Pharmazie,2011,66(4):278-281.
|
[19] |
Kabir N,Ali H,Ateeq M,et al.Silymarin coated gold nanoparticles ameliorates CCl4-induced hepatic injury and cirrhosis through down regulation of hepatic stellate cells and attenuation of Kupffer cells[J].RSC Adv,2014,4:9012-9020.
|
[20] |
Bartneck M,Ritz T,Keul HA,et al.Peptide-functionalized gold nanorods increase liver injury in hepatitis[J].ACS Nano,2012,6(10):8767-8777.
|
[21] |
Choi K,Riviere JE,Monteiro-Riviere NA.Protein corona modulation of hepatocyte uptake and molecular mechanisms of gold nanoparticle toxicity[J].Nanotoxicology,2017,11(1):64-75.
|
[22] |
Iimuro Y,Nishio T,Morimoto T,et al.Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat[J].Gastroenterology,2003,124(2):445-458.
|
[23] |
Arias M,Sauer-Lehnen S,Treptau J,et al.Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats[J].BMC Gastroenterol,2003,3:29.
|
[24] |
Chen P,Li J,Huo Y,et al.Adenovirus-mediated expression of orphan nuclear receptor NR4A2 targeting hepatic stellate cell attenuates liver fibrosis in rats[J].Sci Rep,2016,6:33593.
|
[25] |
Kinoshita K,Iimuro Y,Otogawa K,et al.Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats[J].Gut,2007,56(5):706-714.
|
[26] |
Kim JK, Lee JI, Paik YH, et al. A single adenovirus-mediated relaxin delivery attenuates established liver fibrosis in rats[J].J Gene Med,2016,18(1/2/3):16-26.
|
[27] |
Rezvani M,Español-Suñer R,Malato Y,et al.In vivo hepatic reprogramming of myofibroblasts with AAV vectors as a therapeutic strategy for liver fibrosis[J].Cell Stem Cell,2016,18(6):809-816.
|
[28] |
Song G,Pacher M,Balakrishnan A,et al.Direct reprogramming of hepatic myofibroblasts into hepatocytes in vivo attenuates liver fibrosis[J].Cell Stem Cell,2016,18(6):797-808.
|
[29] |
Lee YS,Jeong WI.Retinoic acids and hepatic stellate cells in liver disease[J].J Gastroenterol Hepatol,2012, 27:75-79.
|
[30] |
Kawaguchi R,Yu J,Honda J,et al.A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A[J].Science,2007,315(5813):820-825.
|
[31] |
Sato Y,Murase K,Kato J,et al.Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone[J].Nat Biotechnol,2008,26(4):431-442.
|
[32] |
Zhang Z, Wang C, Zha Y, et al. Corona-directed nucleic acid delivery into hepatic stellate cells for liver fibrosis therapy[J].ACS Nano,2015,9(3):2405-2419.
|
[33] |
Duong HT,Dong Z,Su L,et al.The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension[J].Small,2015,11(19):2291-2304.
|
[34] |
Marcelino J,Mcdevitt CA.Attachment of articular cartilage chondrocytes to the tissue form of type VI collagen[J].Biochim Biophys Acta,1995,1249(2):180-188.
|
[35] |
Beljaars L,Molema G,Schuppan D,et al.Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor[J].J Biol Chem,2000,275(17):12743-12751.
|
[36] |
Yang J,Hou Y,Ji G,et al.Targeted delivery of the RGD-labeled biodegradable polymersomes loaded with the hydrophilic drug oxymatrine on cultured hepatic stellate cells and liver fibrosis in rats[J].Eur J Pharm Sci,2014,52:180-190.
|
[37] |
Li F,Sun JY,Wang JY,et al.Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis[J].J Control Release,2008,131:77-82.
|
[38] |
Beljaars L, Olinga P, Molema G, et al. Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin(M6P(28)-HSA)[J].Liver,2001,21(5):320-328.
|
[39] |
Beljaars L,Molema G,Weert B,et al.Albumin modified with mannose 6-phosphate:a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells[J].Hepatology,1999,29(5):1486-1493.
|
[40] |
Luk JM,Zhang QS,Lee NP,et al.Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model[J].Liver Int,2010,27(4):548-557.
|
[41] |
Ye Z,Cheng K,Guntaka RV,et al.Targeted delivery of a triplex-forming oligonucleotide to hepatic stellate cells.[J].Biochemistry,2005,44(11):4466-4476.
|
[42] |
Borkham-kamphorst E,Kovalenko E,Roeyen CR,et al.Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury[J].Lab Invest,2008,88(10):1090-1100.
|
[43] |
Bansal R,Prakash J,de Ruijter M,et al.Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis[J].Mol Pharm,2011,8(5):1899-1909.
|
[44] |
Bansal R,Prakash J,De Ruiter M,et al.Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo[J].J Control Release,2014,179(1):18-24.
|
[45] |
Craparo EF,Triolo D,Pitarresi G,et al.Galactosylated micelles for a ribavirin prodrug targeting to hepatocytes[J].Biomacromolecules,2013,14(6):1838-1849.
|
[46] |
Morille M,Passirani C,Letrou-Bonneval E,et al.Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting[J].Int J Pharm,2009,379(2):293-300.
|
[47] |
Mandal AK,Das S,Basu MK,et al.Hepatoprotective activity of liposomal flavonoid against arsenite-induced liver fibrosis[J].J Parmacol Exp Ther,2007,320(3):994-1001.
|
[48] |
Mao SJ,Hou SX,He R,et al.Uptake of albumin nanoparticle surface modified with glycyrrhizin by primary cultured rat hepatocytes[J].World J Gastroentero,2005,11(20):3075-3079.
|
[49] |
Liang B,Guo XL,Jin J,et al.Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury[J].World J Gastroentero,2015,21(17):5271-5280.
|
[50] |
Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis[J].J Hepatol,2014,60(5):1090-1096.
|
[51] |
Bagalkot V,Deiuliis JA,Rajagopalan S,et al.“Eat me” imaging and therapy[J].Adv Drug Deliver Rev,2016,99(Pt A):2-11.
|
[52] |
Ogawa M,Uchino R,Kawai A,et al.PEG modification on(111)In-labeled phosphatidyl serine liposomes for imaging of atherosclerotic plaques[J].Nucl Med Biol,2015,42(3):299-304.
|
[53] |
Wang J,Pan W,Wang Y,et al.Enhanced efficacy of curcumin with phosphatidylserine-decorated nanoparticles in the treatment of hepatic fibrosis[J].Drug Deliv,2018,25(1):1-11.
|
[54] |
Zhang YN,Poon W,Tavares AJ,et al.Nanoparticle-liver interactions:cellular uptake and hepatobiliary elimination[J].J Control Release,2016,240:332-348.
|
[55] |
Bonepally CR,Gandey SJ,Bommineni K,et al.Preparation,characterisation and in vivo evaluation of silybin nanoparticles for the treatment of liver fibrosis[J].Trop J Pharm Res,2013,12(1):1-6.
|
[56] |
Wan AN, Xu DS, Cai YF, et al. Anti-liver fibrosis activities of human insulin-like growth factor-1 in vitro[J].J China Pharm Univ(中国药科大学学报),2017,48(4):476-482.
|
[57] |
Bataller R,Brenner DA.Liver fibrosis[J].J Clin Invest,2005,115(2):209-218.
|
[1] | YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202 |
[2] | LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901 |
[3] | WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902 |
[4] | YU Jiayu, LIN Zezhi, CAO Wei, ZHANG Jianjun, WEI Yuanfeng, GAO Yuan, QIAN Shuai. Research progress of bio-metal organic frameworks in drug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 23-33. DOI: 10.11665/j.issn.1000-5048.20221111003 |
[5] | ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403 |
[6] | LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114 |
[7] | FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302 |
[8] | CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203 |
[9] | WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303 |
[10] | TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572. |